Clinical Trials Logo

Clinical Trial Summary

It is a prospective case-control study with women diagnosed early rheumatoid arthritis. Three therapeutic failures were considered: failure 1 - to the first Disease-modifying antirheumatic drugs (DMARDs) (methotrexate); failure 2 - to the second DMARDs (leflunomide) and failure 3 - to the first immunobiological drugs (adalimumab). Ultrasound was performed bilaterally on the 2nd and 3rd metacarpophalangeal joints (MCFs), proximal interphalangeal joints (IFPs), and wrists (US10). Ultrasound measurements (qualitative and semi-quantitative) evaluated: 1 - inflammatory: synovial and tenosynovial proliferation in gray scale and power Doppler (0-3); 2 - joint damage: bone erosion (qualitative and semi-quantitative) and cartilage damage (qualitative and semi-quantitative). Clinical and laboratory variables were also assessed blindly at baseline and after 12, 24 e 48 weeks.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04752748
Study type Observational
Source Federal University of São Paulo
Contact
Status Completed
Phase
Start date August 2014
Completion date August 2016

See also
  Status Clinical Trial Phase
Completed NCT01768923 - Early RA Vascular Randomised Controlled Study N/A
Completed NCT01762176 - Early RA MRI Early Intensive Treatment Study N/A
Completed NCT01185301 - Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA) Phase 3
Recruiting NCT03755258 - Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis Phase 1
Recruiting NCT03389711 - INCMNSZ - Rheumatoid Arthritis Cohort
Completed NCT00195663 - Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis Phase 3